Module

Important Advances in the Role of Trastuzumab in Breast Cancer

Source: Breast Cancer Annual Update 2005

Important Advances in the Role of Trastuzumab in Breast Cancer


CME Program Director: Clifford A. Hudis, MD

Faculty:

  • Mark D. Pegram, MD

CME CREDIT INFORMATION

Release Date: 11/30/05

Expiration Date: 11/29/06


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the various mechanisms of action by which trastuzumab works in the treatment of breast cancer.
  • Discuss recent clinical trial data regarding use of trastuzumab in the adjuvant treatment of breast cancer.
  • Review mechanisms of resistance to trastuzumab.

Topics covered include:

  • Introduction
  • Antibody-Dependent Cell-Mediated Cytotoxicity and Antibody Activity
  • Trastuzumab for Metastatic Breast Cancer
  • Clinical Efficacy of Trastuzumab in the Adjuvant Setting
  • Safety of Trastuzumab
  • Molecular Determinants of Trastuzumab Response/Resistance
  • Future Directions
  • Summary—Implications for Clinical Practice
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.